Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 4 Serum clinical safety markers, part I

Variable	T1	T2	T3	Time*group	Timegroupgender
Cholesterol (mg/dL)
PLA	155 ± 37	154 ± 34	161 ± 32	Time p = 0.07	GTGe p = 0.38
LD	151 ± 28	150 ± 26	160 ± 28	*GT p = 0.001**
HD	174 ± 33	162 ± 33 ^†	160 ± 32 ^†	*GT p = 0.001**
HDL (mg/dL)
PLA	49 ± 10	51 ± 12	55 ± 12	Time p = 0.08	GTGe p = 0.99
LD	47 ± 11	50 ± 12	51 ± 12	G*T p = 0.16
HD	53 ± 16	49 ± 15	52 ± 16	G*T p = 0.16
LDL (mg/dL)
PLA	89.4 ± 28.9	83.4 ± 28.9	87.7 ± 23.9	Time p = 0.001	GTGe p = 0.38
LD	85.0 ± 19.8	78.9 ± 17.8	86.9 ± 22.2	*GT p = 0.024**
HD	103.0 ± 22.1	89.3 ± 20.5 ^†	89.2 ± 19.9 ^†	*GT p = 0.024**
Cholesterol/HDL
PLA	3.3 ± 0.9	3.1 ± 0.9	3.0 ± 0.8	Time p = 0.19	GTGe p = 0.48
LD	3.2 ± 0.8	3.0 ± 0.8	3.2 ± 0.9	G*T p = 0.77
HD	35 ± 0.9	3.3 ± 0.9	3.3 ± 0.9	G*T p = 0.77
Triglycerides (mg/dL)
PLA	67 ± 25	77 ± 31	73 ± 31	Time p = 0.21	GTGe p = 0.73
LD	80 ± 45	93 ± 50	97 ± 50	G*T p = 0.63
HD	87 ± 39	92 ± 40	83 ± 36	G*T p = 0.63
Glucose (mg/dL)
PLA	86 ± 8	86 ± 8	86 ± 6	Time p = 0.14	GTGe p = 0.44
LD	87 ± 7	86 ± 8	90 ± 8	G*T p = 0.55
HD	84 ± 9	86 ± 9	86 ± 7	G*T p = 0.55

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ^†, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed